Proof-of-concept Programs

DIBI is expected to be effective in treating gastrointestinal infections and would be administered orally to get it directly to the area of infection. Initial treatment indications for oral DIBI include infections caused by Clostridioides difficile (formerly Clostridium difficile).

Cancer cells have an increased need for iron and anti-cancer iron chelators have been sought. DIBI fulfills the target profile and has shown potential in vitro as a monotherapy for breast cancer as well as a chemosensitizer making other chemotherapeutics more than 10 times more potent against breast cancer cells in vitro.